EMA Authorised: Dafiro (amlodipine;valsartan) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Dafiro, a fixed-dose combination of amlodipine and valsartan, for the treatment of hypertension, with Novartis Europharm Limited as the marke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Dafiro (amlodipine; valsartan)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Novartis Europharm Limited. Decision date: 19/11/2025